Open Access

MicroRNA‑362‑5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein

  • Authors:
    • Xiaoli Wei
    • Mengru Gao
    • Yaser Ahmed
    • Min Gao
    • Wenbo Liu
    • Yiyin Zhang
    • Xiaoque Xie
    • Qihong Zhao
    • Hua Wang
    • Kangsheng Gu
  • View Affiliations

  • Published online on: June 19, 2019     https://doi.org/10.3892/ol.2019.10496
  • Pages: 1607-1616
  • Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemotherapy resistance is a major obstacle to the effective treatment of patients with gastric cancer (GC). Mounting evidence has indicated that the dysregulation of microRNAs (miRNAs) is associated with the sensitivity of cancer cells to chemotherapy. However, the mechanisms underlying miRNA‑mediated chemoresistance in GC cells remain to be elucidated. The present study aimed to identify functional miRNAs that may regulate the sensitivity of human GC cells to cisplatin (DDP) treatment. miRNA microarray analysis was used to identify differentially expressed miRNAs between the human cisplatin‑sensitive GC cell line SGC7901 and the corresponding cisplatin‑resistant cell line SGC7901/DDP. miRNA (miR)‑362‑5p, which is associated with numerous types of tumors, was identified to be downregulated in the SGC7901/DDP cell line. However, the biological role of miR‑362‑5p in SGC7901/DDP cells remains to be explored. The expression level of miR‑362‑5p was demonstrated to be reduced in SGC7901/DDP cells compared with SGC7901 cells by reverse transcription‑quantitative PCR. Upregulation of miR‑362‑5p significantly increased cisplatin sensitivity and cisplatin‑induced apoptosis, whereas downregulation of miR‑362‑5p attenuated these effects. Databases predicted that suppressor of zeste 12 protein (SUZ12) may function as a target of miR‑362‑5p. In addition, the mRNA and protein expression levels of SUZ12 in SGC7901/DDP cells were significantly higher compared with SGC7901 cells and negatively associated with miR‑362‑5p expression. MTT and western blot analysis assays confirmed that knockdown of SUZ12 enhanced cisplatin sensitivity and decreased NF‑κB/p65 protein levels in SGC7901/DDP cells. In addition, upregulation of miR‑362‑5p in SGC7901/DDP cells decreased the protein expression level of SUZ12, whereas downregulation of miR‑362‑5p increased the SUZ12 expression level. The results of the present study suggested that dysregulated miR‑362‑5p may target SUZ12 to promote the development of cisplatin resistance and attenuate cisplatin‑induced apoptosis. Therefore, miR‑362‑5p upregulation combined with cisplatin treatment may serve as a promising therapeutic strategy for patients with cisplatin‑resistant GC.
View Figures
View References

Related Articles

Journal Cover

August-2019
Volume 18 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wei X, Gao M, Ahmed Y, Gao M, Liu W, Zhang Y, Xie X, Zhao Q, Wang H, Gu K, Gu K, et al: MicroRNA‑362‑5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein. Oncol Lett 18: 1607-1616, 2019.
APA
Wei, X., Gao, M., Ahmed, Y., Gao, M., Liu, W., Zhang, Y. ... Gu, K. (2019). MicroRNA‑362‑5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein. Oncology Letters, 18, 1607-1616. https://doi.org/10.3892/ol.2019.10496
MLA
Wei, X., Gao, M., Ahmed, Y., Gao, M., Liu, W., Zhang, Y., Xie, X., Zhao, Q., Wang, H., Gu, K."MicroRNA‑362‑5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein". Oncology Letters 18.2 (2019): 1607-1616.
Chicago
Wei, X., Gao, M., Ahmed, Y., Gao, M., Liu, W., Zhang, Y., Xie, X., Zhao, Q., Wang, H., Gu, K."MicroRNA‑362‑5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein". Oncology Letters 18, no. 2 (2019): 1607-1616. https://doi.org/10.3892/ol.2019.10496